This is the 4th installment in our series on how the Medical Affairs (MA) function is changing in today’s biopharma industry. The paper takes a close look at how MA is becoming a key player in holistic “molecule level” strategy development, as opposed to its more traditional role of focusing on strategy within its own functional area.
